12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simponi golimumab: Phase III data

The double-blind, international Phase III PURSUIT trial in 774 patients showed that induction therapy with low- and high-dose subcutaneous Simponi each met the primary endpoint of a greater proportion of patients achieving a clinical response at week 6 vs. placebo (51.8% and 55%, respectively, vs. 29.7%, p<0.0001 for both). Both doses of Simponi also met the secondary endpoints of a greater proportion of patients achieving clinical remission (18.7% and 17.8%, respectively, vs. 6.3%, p<0.0001 for both) and mucosal healing vs. placebo (43.2% and 45.3%, respectively, vs. 28.5%, p=0.0005 for both). Additionally, a significantly greater proportion of patients receiving low- and high-dose Simponi reported improvements in health-related quality of life...

Read the full 521 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >